

Table S1 Patients' treatment regimens and surgical details

Patients	Neoadjuvant medication regimen	Neoadjuvant therapy cycles	Extent of resection	Margin status	Postoperative treatment
P1	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (300 mg, D1)	2	Pneumonectomy	R0	NA
P2	Etoposide (100 mg/m ² , D1–3) + cisplatin (40 mg/m ² , D1–3) + atezolizumab (1,200 mg, D1)	4	Pneumonectomy	R0	Irinotecan (180 mg/m ² , D1 q21D) + carboplatin (AUC =5, D1 q21D) ×3 cycles; cranial radiotherapy (2.5 Gy × 10 f, 5 f/week) ×1 cycle
P3	Etoposide (100 mg/m ² , D1–3) + cisplatin (40 mg/m ² , D1–3) + atezolizumab (1,200 mg, D1)	4	Lobectomy	R0	Atezolizumab (1,200 mg, D1) ×1 cycle; cranial radiotherapy (2.5 Gy × 10 f, 5 f/week) ×1 cycle
P4	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	4	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + cisplatin (40 mg/m ² , D1–3) + atezolizumab (1,200 mg, D1) ×1 cycle + atezolizumab (1,200 mg, D1) ×4 cycles
P5	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	2	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1) ×4 cycles + atezolizumab (1,200 mg, D1) ×2 cycles
P6	Etoposide (100 mg/m ² , D1–3) + cisplatin (25 mg/m ² , D1–2) + pembrolizumab (200 mg, D1)	4	Lobectomy	R0	Irinotecan (100 mg/m ² , D1, D8) + cisplatin (50 mg/m ² , D1, D8) ×5 cycles
P7	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×2 cycles + atezolizumab (1,200 mg, D1) ×1 cycle
P8	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×3 cycles
P9	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×1 cycle + atezolizumab (1,200 mg, D1) ×3 cycles
P10	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (4.5 mg/kg, D1)	4	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (4.5 mg/kg, D1) ×2 cycles
P11	Etoposide (100 mg/m ² , D1–5) + lobaplatin (50 mg/m ² , D1) + serplulimab (300 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–5) + Lobaplatin (50 mg/m ² , D1) ×1 cycle
P12	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (4.5 mg/kg, D1)	2	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) ×1 cycle
P13	Etoposide (100 mg/m ² , D1–3) + cisplatin (80 mg/m ² , D1–3) + serplulimab (4.5 mg/kg, D1)	2	Pneumonectomy	R0	NA
P14	Etoposide (100 mg/m ² , D1–3) + cisplatin (80 mg/m ² , D1–3) + atezolizumab (1,200 mg, D1)	4	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×2 cycles + atezolizumab (1,200 mg, D1) ×1 cycle

Table S1 (continued)

Table S1 (continued)

Patients	Neoadjuvant medication regimen	Neoadjuvant therapy cycles	Extent of resection	Margin status	Postoperative treatment
P15	Etoposide (100 mg/m ² , D1–3) + cisplatin (30 mg/m ² , D1–3) + serplulimab (4.5 mg/kg, D1)	4	Lobectomy	R0	NA
P16	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	4	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×2 cycles + atezolizumab (1,200 mg, D1) ×4 cycles
P17	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	4	Pneumonectomy	R0	Atezolizumab (1,200 mg, D1) ×12 cycles
P18	Etoposide (100 mg/m ² , D1–3) + nedaplatin (60 mg/m ² , D1–2) + serplulimab (300 mg, D1)	3	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (60 mg/m ² , D1–2) + serplulimab (300 mg, D1) ×4 cycles
P19	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×2 cycles + etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (300 mg, D1) ×2 cycles
P20	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (4.5 mg/kg, D1)	4	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + serplulimab (4.5 mg/kg, D1) ×5 cycles + serplulimab (4.5 mg/kg, D1) ×14 cycles
P21	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	2	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1) ×4 cycles + atezolizumab (1,200 mg, D1) ×14 cycles
P22	Nab-paclitaxel (160 mg/m ² , D1, D8) + nedaplatin (80 mg/m ² , D1) + tislelizumab (200 mg, D1)	2	Lobectomy	R0	Nab-paclitaxel (160 mg/m ² , D1, D8) + nedaplatin (80 mg/m ² , D1) + tislelizumab (200 mg, D1) ×1 cycle
P23	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1) ×2 cycles + atezolizumab (1,200 mg, D1) ×23 cycles
P24	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	4	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1) ×2 cycles + atezolizumab (1,200 mg, D1) ×10 cycles
P25	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	4	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×1 cycle
P26	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	NA
P27	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	2	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1) ×1 cycle + etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) ×3 cycles
P28	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Atezolizumab (1,200 mg, D1) ×2 cycles

Table S1 (continued)

Table S1 (continued)

Patients	Neoadjuvant medication regimen	Neoadjuvant therapy cycles	Extent of resection	Margin status	Postoperative treatment
P29	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Pneumonectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×3 cycles + atezolizumab (1,200 mg, D1) ×5 cycles
P30	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + atezolizumab (1,200 mg, D1) ×3 cycles + atezolizumab (1,200 mg, D1) ×1 cycle
P31	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) ×2 cycles
P32	Etoposide (100 mg/m ² , D1–3) + nedaplatin (80 mg/m ² , D1) + camrelizumab (200 mg, D1)	3	Lobectomy	R0	NA
P33	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	2	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×4 cycles
P34	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1)	3	Lobectomy	R0	Etoposide (100 mg/m ² , D1–3) + carboplatin (AUC =5, D1) + atezolizumab (1,200 mg, D1) ×1 cycle

Margin status: according to the AJCC 8th edition. All patients underwent dissection of at least three stations of mediastinal lymph nodes and three stations of hilar lymph nodes. AJCC, American Joint Committee on Cancer; AUC, area under the curve; D, day; NA, not available; q21D, every 21 days.